Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's $1.3 Bil. Inverness Buy Would End Royalty-Based Relationship

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's $1.3 bil. proposed acquisition of Inverness Medical Technology's diabetes care business builds on the firms' ongoing glucose meter and strip supply relationship begun in 1995.
Advertisement

Related Content

Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Lifescan Looks To InDuo Launch To Help Sustain 2001 Diabetes Care Growth
Lifescan Looks To InDuo Launch To Help Sustain 2001 Diabetes Care Growth
Disetronic, Type 2 Diabetes In MiniMed's Sights Following Medtronic Merger
Disetronic, Type 2 Diabetes In MiniMed's Sights Following Medtronic Merger
J&J/Inverness
Cygnus GlucoWatch Pilot Marketing Program To Begin In April
Abbott Labs entering blood glucose monitoring market with $876 mil. MediSense buy.
Abbott Labs entering blood glucose monitoring market with $876 mil. MediSense buy.
Advertisement
UsernamePublicRestriction

Register

MT014867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel